Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer
European Journal of Cancer · 2026-11 · 248 · 117079
DOI: 10.1016/j.ejca.2026.117079 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Elena Castro und 19 weiteren Autor:innen. Beteiligte Einrichtung: Insituto de Investigación del Hospital Universitario 12 de Octubre (imas12), Madrid, Spain. Electronic address: ecastro.imas12@h12o.es. Hauptthemen laut MEDLINE: Phthalazines, Prostatic Neoplasms, Castration-Resistant, Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Insituto de Investigación del Hospital Universitario 12 de Octubre (imas12), Madrid, Spain. Electronic address: ecastro.imas12@h12o.es.
- Pfizer Inc., South San Francisco, CA, USA.
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
- Medical Oncology, Swedish Cancer Institute, Seattle, WA, USA.
- Department of Urology, University Medical Center Groningen, Groningen, the Netherlands.
Förderung
- Pfizer Inc
Zitieren
APA
Castro, E., Douglas Laird, A., Mehra, N., Dorff, T., Zhao, S., van Oort, I., Gasparro, D., Calabrò, F., Pignata, S., Geczi, L., Barthélémy, P., Kilari, D., Graf, R. P., Chen, H. C., Healy, C. G., Scagliotti, G. V., Chelliserry, J., Kennedy, D., Fizazi, K., & de Bono, J. S. (2026). Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer. European Journal of Cancer, 248, 117079. https://doi.org/10.1016/j.ejca.2026.117079
Vancouver
Castro E, Douglas Laird A, Mehra N, Dorff T, Zhao S, van Oort I, et al. Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer. European Journal of Cancer. 2026;248:117079. doi:10.1016/j.ejca.2026.117079
BibTeX
@article{Castro2026,
author = {Castro, Elena and Douglas Laird, A and Mehra, Niven and Dorff, Tanya and Zhao, Song and van Oort, Inge and Gasparro, Donatello and Calabrò, Fabio and Pignata, Sandro and Geczi, Lajos and Barthélémy, Philippe and Kilari, Deepak and Graf, Ryon P and Chen, Hsiang-Chun and Healy, Cynthia G and Scagliotti, Giorgio V and Chelliserry, Jijumon and Kennedy, Dana and Fizazi, Karim and de Bono, Johann S},
title = {Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117079},
doi = {10.1016/j.ejca.2026.117079}
}
EUVIMED